Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Vulvovaginal Candidiasis
Conditions
Recurrent Vulvovaginal Candidiasis
Trial Timeline
Oct 21, 2019 → Nov 29, 2021
NCT ID
NCT04029116About Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet is a phase 3 stage product being developed by Scynexis for Recurrent Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04029116. Target conditions include Recurrent Vulvovaginal Candidiasis.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Vulvovaginal Candidiasis were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04029116 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Vulvovaginal Candidiasis